Drug-induced Caspase-3 Activation in A Ewing Tumor Cell Line and Primary Ewing Tumor Cells

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 145-149

  Mauz Körholz, Christine ^a   Kachel, Martin ^a   Harms Schirra, Britt ^b   Klein Vehne, Anne ^b   Tunn, Peter Ulrich ^c   Körholz, Dieter ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Evotec Technologies GmbH   (Germany)

^c NONE

Author keywords

Caspase 3 activation; Drug sensitivity testing; Drug induced apoptosis; Ewing tumor

Indexed keywords

CASPASE; CASPASE 3; DACTINOMYCIN; ETOPOSIDE;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL ASSAY; CELL DEATH; CELL ISOLATION; CELL KILLING; CELL STIMULATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; METASTASIS; PATIENT SELECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TECHNIQUE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASPASE 3; CASPASES; CELL LINE, TUMOR; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ETOPOSIDE; HUMANS; MALE; SARCOMA, EWING'S; TUMOR CELLS, CULTURED;

EID: 1442277099     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Price CH and Jeffree GM: Incidence of bone sarcoma in SW England 1946-74 in relation to age, sex, tumour site and histology. Br J Cancer 36: 511-522, 1977.
2. Craft AW, Cotterill SJ, Bullimore JA and Pauton AD: Long-term results from the first UKCCSG Ewing's tumour study (ET-1). Eur J Cancer 33: 1061-1069, 1997.
3. Göbel V, Jürgens H, Etspüler G, Kemperdick H, Jungbluth RM, Stienen U and Göbel U: Prognostic significance of tumour volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 113: 187-191, 1987.
4. Sauer R, Jürgens H, Burgers JM, Dunst J, Hawlicek R and Michaelis J: Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's sarcoma study group of the German Society of Pediatric Oncology CESS 81. Radiother Oncol 10: 101-110, 1987.
5. Paulussen M, Braun-Munzinger G, Burdach S, Deneke S, Dunst J, Fellinger E, Göbel U, Mittler U, Treuner J and Voute PA: Results of treatment of primary exclusively pulmonary metastatic Ewing sarcoma. A retrospective analysis of 41 patients. Klin Pädiatr 205: 210-216, 1993.
6. Mendenhall CM, Marcus RB, Enneking WF, Springfield DS, Thar TL and Million RR: The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer 51: 913-917, 1983.
7. Lewis I, Oberlin O, Judson I, Gadner H, Exner U, Jürgens H and Craft AW: EURO-Ewing 99-Ewing tumour study protocol.
8. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ and Pieters R: In vitro drug resistance as independent prognostic factor in the study COALL-05-92 treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Pädiatr 211: 233-328, 1999.
9. Fulda S, Sieverts H, Friesen C, Herr I and Debatin K-M: The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57: 3823-3829, 1997.
10. Muldoon LL, Ealker-Rosenfeld SL, Hale C, Purcell SE, Bennett LC and Neuwelt EA: Rescue from enhanced alkylator induced cell death with low molecular weight sulfur containing chemoprotectants. J Pharmacol Exper Therap 296: 797-805, 2001.
11. Sheikh MS, Antinore MJ, Huang Y and Fornace AJ: Ultraviolet irradiation induced apoptosis is mediated via ligand independent activation of tumour necrosis factor receptor 1. Oncogene 17: 2555-2563, 1998.
12. Martinsson P, Liminga G, Nygren P and Larsson R: Characteristics of etoposide induced cell death in the U-937 lymphoma cell line. Anticancer Drugs 12: 699-705, 2001.
13. Narita Y, Asai A, Kuchino Y and Kirino T: Actinomycin D and staurosporine, potent apoptosis inducers in vitro are potentially effective chemotherapeutic agents against glioblastoma multiforme. Cancer Chemother Pharmacol 45: 149-156, 2000.
14. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741, 1999.
15. Drexler HG, Dirks W, MacLeod RAF, Quentmeier H, Steube K and Uphoff CC (eds): DSMZ Catalogue of Human and Animal Cell Lines, seventh edition, Braunschweig, Germany, 1999.
16. Herr I and Debatin K-M: Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2614, 2001.
17. Miller TM, Moulder KL, Knudson CM, Creedon DJ, Deshmukh M, Korsmeyer SJ and Johnson EM Jr: Bax deletion further orders the cell death pathway in cerebellar granule cells and suggests a caspase-independent pathway to cell death. J Cell Biol 139: 205-217, 1997.
18. Xiang J, Chao DT and Korsmeyer SJ: Bax-induced cell death may not require interleukin 1-beta-converting enzyme-like proteases. Proc Natl Acad Sci 93: 14559-14563, 1996.
19. Stahnke K, Fulda S, Friesen C, Strauß G and Debatin K-M: Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood 98: 3066-3073, 2001.
20. Brindley CJ, Antoniw P, Newlands ES and Bagshawe KD: Pharmacokinetics and toxicity of the epipodophyllotoxin derivate etoposide (VP16-213) in patients with gastrointestinal chorio-carcinoma and malignant teratoma. Cancer Chemother Pharmacol 15: 66-71, 1985.
21. Tattersall MH, Södergren JE, Dengupta SK, Trites DH, Modest EJ and Frei E 3rd: Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 17: 701-708, 1975.